Drug intelligence / Profile preview

LNK010

Development stage: Preclinical
Lead developer: Lynk Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

LNK010 is an oral small-molecule inhibitor (antagonist) of the interleukin-23 (IL-23) receptor, currently in preclinical development by Lynk Pharmaceuticals. It is designed to target the IL-23 signaling pathway, which plays a critical role in the pathogenesis of various autoimmune and inflammatory diseases. LNK010 is being developed for the treatment of inflammatory bowel disease (IBD) and psoriasis. By blocking the IL-23 receptor, LNK010 aims to modulate the downstream inflammatory cascade and provide a highly effective oral therapeutic option for patients suffering from these chronic conditions.

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on LNK010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNK010.

Explore the full profile